Clinical trial
A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough
NCT02612623 is registered in ClinicalTrials.gov with Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough
- Lead sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 17, 2015
- Completion date
- May 18, 2016
- Enrollment
- 24 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
refractory chronic cough